Deborah Kochevar - Charles River Independent Director
| CRL Stock | USD 229.00 3.10 1.34% |
Director
Dr. Deborah Turner Kochevar, D.V.M., Ph.D. is an Independent Director of Charles River Laboratories International Inc. She is Dean of the Cummings School of Veterinary Medicine at Tufts University since 2006. Dr. Kochevar will assume provost ad interim duties at Tufts University in April 2018. Previously, Dr. Kochevar was a longtime faculty member and administrator at the College of Veterinary Medicine and Biomedical Sciences, Texas AM University, where she held the Wiley Chair of Veterinary Medical Education. Dr. Kochevar is a pastpresident of the Association of American Veterinary Medical Colleges and American College of Veterinary Clinical Pharmacology. Dr. Kochevar is active in the American Veterinary Medical Association, having chaired its Council on Education and the Educational Commission for Foreign Veterinary Graduates. Dr. Kochevar was a director since October 2008. Dr. Kochevar was selected to the Board in recognition of her distinct perspective as a highly distinguished academic and educator in the life sciences. As a boarded diplomate of the American College of Veterinary Clinical Pharmacology, with a Ph.D. in cell and molecular biology combined with a D.V.M. degree, and with a deep knowledge base of comparative medicine and complex animal models, Dr. Kochevar training and experience is particularly suited to understanding and providing insights into the veterinary medical, contract research and drug development support activities that we conduct. Dr. Kochevar also provides the Board with current industry and scientific insights through her ongoing involvement in a broad array of biomedical professional and trade organizations. since 2008.
| Age | 64 |
| Tenure | 16 years |
| Address | 251 Ballardvale Street, Wilmington, MA, United States, 01887 |
| Phone | 781 222 6000 |
| Web | https://www.criver.com |
Charles River Management Efficiency
The company has Return on Asset of 0.0519 % which means that on every $100 spent on assets, it made $0.0519 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1438 %, implying that it generated $0.1438 on every 100 dollars invested. Charles River's management efficiency ratios could be used to measure how well Charles River manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Charles River's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.06 this year, although the value of Return On Tangible Assets will most likely fall to 0.12. At this time, Charles River's Return On Assets are quite stable compared to the past year. Asset Turnover is expected to rise to 0.67 this year, although the value of Intangible Assets will most likely fall to about 480.2 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Surbhi Sarna | Penumbra | 34 | |
| Rebecca Robertson | Tandem Diabetes Care | 57 | |
| Jessica Hopfield | Insulet | 53 | |
| Susan Vogt | Anika Therapeutics | 66 | |
| Thomas Wilder | Penumbra | 56 | |
| Charles Liamos | Insulet | 55 | |
| Joseph Bower | Anika Therapeutics | 78 | |
| Martha Aronson | CONMED | 53 | |
| Dana Mead | Inspire Medical Systems | 61 | |
| Jeffrey Thompson | Anika Therapeutics | 51 | |
| Mudit Jain | Inspire Medical Systems | 49 | |
| Daniel Levangie | Insulet | 64 | |
| Brian Concannon | CONMED | 62 | |
| Shelley Broader | Inspire Medical Systems | 56 | |
| Howard Greene | Tandem Diabetes Care | 75 | |
| Corinne Nevinny | Insulet | 57 | |
| Nilesh Jagatia | Inspire Medical Systems | 50 | |
| Gary Ellis | Inspire Medical Systems | 64 | |
| Jesse Treu | Tandem Diabetes Care | 67 | |
| Michael Minogue | Insulet | 50 | |
| Marc Stapley | Glaukos Corp | 50 | |
Management Performance
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0519 |
Charles River Labora Leadership Team
Elected by the shareholders, the Charles River's board of directors comprises two types of representatives: Charles River inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Charles. The board's role is to monitor Charles River's management team and ensure that shareholders' interests are well served. Charles River's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Charles River's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Craig Thompson, Director | ||
| Robert Bertolini, Independent Director | ||
| Birgit Girshick, Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian | ||
| James Foster, Chairman of the Board, President, Chief Executive Officer | ||
| Joseph LaPlume, Corporate Executive Vice President - Corporate Development and Strategy | ||
| Mark Mintz, Corporate Officer | ||
| Michael Knell, Corporate Senior Vice President Chief Accounting Officer | ||
| George Milne, Lead Independent Director | ||
| Thomas Ackerman, CFO and Corporate Executive VP | ||
| George Llado, Independent Director | ||
| Nancy Andrews, Independent Director | ||
| Victoria Creamer, Corporate Senior Vice President Chief People Officer. | ||
| JeanPaul Mangeolle, Independent Director | ||
| Gina Mullane, Chief VP | ||
| Richard Wallman, Independent Director | ||
| Pr Frearson, Corporate Officer | ||
| David Smith, Chief Financial Officer, Corporate Executive Vice President | ||
| James JD, CEO Chairman | ||
| Matthew Daniel, General VP | ||
| Nancy Gillett, Chief Scientific Officer, Corporate Executive Vice President | ||
| Martin Mackay, Independent Director | ||
| Virginia Wilson, Independent Director | ||
| Flavia Pease, Corporate Executive Vice President | ||
| Emily Hickey, Corporate Senior Vice President - Global Discovery Services | ||
| Amy Cianciaruso, Corporate Officer | ||
| Todd Spencer, Corporate Relations | ||
| David Johst, Corporate Executive Vice President - Human Resources, Chief Administrative Officer, General Counsel | ||
| Deborah Kochevar, Independent Director | ||
| William Barbo, Corporate Executive Vice President and Chief Commercial Officer | ||
| Stephen Chubb, Independent Director | ||
| Richard Reese, Independent Director | ||
| Davide Molho, Corporate Executive Vice President ; President Global Research Models & Services and Preclinical Services Operations | ||
| George Massaro, Independent Director | ||
| Susan Hardy, Corporate Vice President Investor Relations |
Charles Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Charles River a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0519 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 14.83 B | ||||
| Shares Outstanding | 51.51 M | ||||
| Shares Owned By Insiders | 0.97 % | ||||
| Shares Owned By Institutions | 99.03 % | ||||
| Number Of Shares Shorted | 1.91 M | ||||
| Price To Earning | 33.74 X |
Pair Trading with Charles River
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Charles River position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Charles River will appreciate offsetting losses from the drop in the long position's value.Moving together with Charles Stock
| 0.8 | DRRX | Durect Earnings Call This Week | PairCorr |
Moving against Charles Stock
| 0.46 | SBFMW | Sunshine Biopharma | PairCorr |
The ability to find closely correlated positions to Charles River could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Charles River when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Charles River - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Charles River Laboratories to buy it.
The correlation of Charles River is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Charles River moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Charles River Labora moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Charles River can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Charles River Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Charles Stock analysis
When running Charles River's price analysis, check to measure Charles River's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Charles River is operating at the current time. Most of Charles River's value examination focuses on studying past and present price action to predict the probability of Charles River's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Charles River's price. Additionally, you may evaluate how the addition of Charles River to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Charles River's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Charles River. If investors know Charles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Charles River listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.01) | Earnings Share 9.21 | Revenue Per Share 80.61 | Quarterly Revenue Growth (0.08) | Return On Assets 0.0519 |
The market value of Charles River Labora is measured differently than its book value, which is the value of Charles that is recorded on the company's balance sheet. Investors also form their own opinion of Charles River's value that differs from its market value or its book value, called intrinsic value, which is Charles River's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Charles River's market value can be influenced by many factors that don't directly affect Charles River's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Charles River's value and its price as these two are different measures arrived at by different means. Investors typically determine if Charles River is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Charles River's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.